Artiva Biotherapeutics’ (ARTV) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reaffirmed their buy rating on shares of Artiva Biotherapeutics (NASDAQ:ARTV) in a report released on Wednesday morning,Benzinga reports. They currently have a $23.00 price target on the stock.

A number of other research firms have also commented on ARTV. TD Cowen started coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued a “buy” rating on the stock. Cantor Fitzgerald started coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They issued an “overweight” rating and a $23.00 price target on the stock. Jefferies Financial Group began coverage on shares of Artiva Biotherapeutics in a research report on Tuesday, August 13th. They set a “buy” rating and a $21.00 target price on the stock. Finally, Wedbush reaffirmed an “outperform” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Friday, August 30th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $21.25.

Artiva Biotherapeutics Stock Down 4.3 %

ARTV stock opened at $10.06 on Wednesday. The stock’s 50 day moving average is $12.57. Artiva Biotherapeutics has a 52 week low of $9.68 and a 52 week high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.24). As a group, analysts anticipate that Artiva Biotherapeutics will post -4.6 earnings per share for the current year.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several institutional investors and hedge funds have recently bought and sold shares of ARTV. Charles Schwab Investment Management Inc. bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $623,000. BNP Paribas Financial Markets bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $42,000. MetLife Investment Management LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Acuta Capital Partners LLC bought a new stake in Artiva Biotherapeutics in the 3rd quarter valued at $680,000. Finally, RTW Investments LP acquired a new stake in shares of Artiva Biotherapeutics in the 3rd quarter valued at $2,300,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.